Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB25FPRC3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $28,394
Award facts
- Contract value 100% obligated
- $28,393.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $28,393.50 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nucala 100 mg/ml auto-injectors. The contract was executed on August 12, 2025, with an ultimate completion date of August 13, 2025, and carries firm fixed-price terms with no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at $499,999,999 through November 2026, which authorizes the agency to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical items supporting military health facilities.
Nucala (mepolizumab) is a biologic medication used to treat severe asthma and eosinophilic conditions. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with a robust portfolio of contract awards covering branded and generic prescription drugs, biologics, vaccines, and specialty medical products to Department of Defense healthcare sites nationwide. The company's strategic positioning as a woman-owned small business has enabled it to compete effectively for federal pharmaceutical procurement opportunities while maintaining consistent delivery performance across diverse medical product categories.
Quick answers
Who was awarded contract SPE2DB25FPRC3?
SPE2DB25FPRC3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 12, 2025.
How much is contract SPE2DB25FPRC3 worth?
The government has obligated $28,394 on SPE2DB25FPRC3.
Is contract SPE2DB25FPRC3 an order under another contract?
Yes. SPE2DB25FPRC3 is a delivery order under SPE2DB20D9127, an indefinite delivery contract.
Was contract SPE2DB25FPRC3 competed?
The extent of competition for SPE2DB25FPRC3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award